Calcitonin microinjection into the periaqueductal gray impairs contextual fear conditioning in the rat

被引:6
|
作者
Aboufatima, R
Chait, A [1 ]
Dalal, A
de Beaurepaire, R
机构
[1] Univ Cadi Ayyad, Fac Sci Semlalia, Unite Ecophysiol Anim, Marrakech 4000, Morocco
[2] Hop Paul Guiraud, Lab Psychopharmacol, F-94806 Villejuif, France
关键词
memory; depression; acetylcholine; glutamate; serotonin;
D O I
10.1016/S0304-3940(99)00749-1
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
We have previously proposed that behavioral alterations induced by salmon calcitonin in the rat provide an animal model of depression, As depression is characterized by context-related anxiety, behavioral inhibition and alterations in memory processing, we tested the effects of microinjections of salmon calcitonin into the periaqueductal gray matter (PAG) on contextual fear conditioning in the rat. In a first experiment, calcitonin or saline were microinjected into the PAG before the training phase and before the testing phase of a conditional fear testing procedure. In a second experiment, calcitonin or saline were injected before and immediately after the training phase. When given before the training phase, calcitonin had no effects on immediate postshock freezing but produced significant deficits in contextual freezing (24 h after footshock) in comparison with controls. When given immediately after the footshocks, calcitonin impaired contextual fear. These results suggest that calcitonin receptor stimulation in the PAG can alter the acquisition and consolidation of contextual fear behavior processes. (C) 1999 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:101 / 104
页数:4
相关论文
共 50 条
  • [21] Anti-aversive effect of 2-arachidonoylglycerol in the dorsolateral periaqueductal gray of male rats in contextual fear conditioning and Vogel tests
    Brianis, Rayssa C.
    Lima, Rita C.
    Moreira, Fabricio A.
    Aguiar, Daniele C.
    BEHAVIOURAL PHARMACOLOGY, 2022, 33 (2-3): : 213 - 221
  • [22] Modulation of Gene Expression in Contextual Fear Conditioning in the Rat
    Federighi, Giuseppe
    Traina, Giovanna
    Macchi, Monica
    Ciampini, Cristina
    Bernardi, Rodolfo
    Baldi, Elisabetta
    Bucherelli, Corrado
    Brunelli, Marcello
    Scuri, Rossana
    PLOS ONE, 2013, 8 (11):
  • [23] Injections of corticotropin-releasing factor into the periaqueductal gray enhance Pavlovian fear conditioning
    Tershner, SA
    Helmstetter, FJ
    PSYCHOBIOLOGY, 1996, 24 (01) : 49 - 56
  • [24] Prior chronic nicotine impairs cued fear extinction but enhances contextual fear conditioning in rats
    Tian, S.
    Gao, J.
    Han, L.
    Fu, J.
    Li, C.
    Li, Z.
    NEUROSCIENCE, 2008, 153 (04) : 935 - 943
  • [25] Neural Correlates of Fear in the Periaqueductal Gray
    Watson, Thomas C.
    Cerminara, Nadia L.
    Lumb, Bridget M.
    Apps, Richard
    JOURNAL OF NEUROSCIENCE, 2016, 36 (50): : 12707 - 12719
  • [26] Effect of dorsal periaqueductal gray lesion on cardiovascular and behavioural responses to contextual conditioned fear in rats
    Leman, S
    Dielenberg, RA
    Carrive, R
    BEHAVIOURAL BRAIN RESEARCH, 2003, 143 (02) : 169 - 176
  • [27] Galanin administration into the prelimbic cortex impairs consolidation and expression of contextual fear conditioning
    Hooversmith, Jessica M.
    Bhatti, Dionnet L.
    Holmes, Philip, V
    BEHAVIOURAL BRAIN RESEARCH, 2019, 375
  • [28] Opioid receptors in the midbrain periaqueductal gray regulate prediction errors during Pavlovian fear conditioning
    McNally, GP
    Cole, S
    BEHAVIORAL NEUROSCIENCE, 2006, 120 (02) : 313 - 323
  • [29] Effects of chemogenetic excitation or inhibition of the ventrolateral periaqueductal gray on the acquisition and extinction of Pavlovian fear conditioning
    Arico, Carolyn
    Bagley, Elena E.
    Carrive, Pascal
    Assareh, Neda
    McNally, Gavan P.
    NEUROBIOLOGY OF LEARNING AND MEMORY, 2017, 144 : 186 - 197
  • [30] Immunomodulation mediated by microinjection of morphine into the periaqueductal gray matter of the mesencephalon
    Suo, JL
    Weber, RJ
    DRUGS OF ABUSE, IMMUNOMODULATION, AND AIDS, 1998, 437 : 177 - 182